World Stroke Congress Research Articles

16th World Stroke Congress, 23-26 October 2024, Abu Dhabi, UAE

16th World Stroke Congress, 23-26 October 2024, Abu Dhabi, UAE

Advances in neurovascular research: Scientific highlights from the 15th world stroke congress

Advances in neurovascular research: Scientific highlights from the 15th world stroke congress

15th World Stroke Congress, 10-12 October 2023, Toronto, Canada.

15th World Stroke Congress, 10-12 October 2023, Toronto, Canada.

15th World Stroke Congress, 10-12 October 2023, Toronto, Canada: Late Breaking Abstracts.

15th World Stroke Congress, 10-12 October 2023, Toronto, Canada: Late Breaking Abstracts.

Iranian stroke model-how to involve health policymakers

Iranian stroke model-how to involve health policymakers

14th World Stroke Congress, Singapore, 26-29 October 2022

Free accessAbstractFirst published online October 25, 202214th World Stroke Congress, Singapore, 26-29 October 2022Volume 17, Issue 3_supplhttps://doi.org/10.1177/17474930221125973

Update of the World Stroke Organization Activities.

Update of the World Stroke Organization Activities.

How can the World Stroke Organization (WSO) optimize education in stroke medicine around the world? Report of the 2018 WSO Global Stroke Stakeholder Workshop.

Education in stroke is relevant to stroke survivors, clinicians, care providers, and healthcare system administrators and is of special importance in resource-limited settings. The World Stroke Organization Education Committee undertook a program of work, culminating in a focused workshop, to establish the key educational priorities, and work toward maximizing the WSOs impact on the global burden of stroke. A facilitated workshop took place during the World Stroke Congress in Montreal, Canada in October 2018. The workshop was developed using opinions on priority topics for World Stroke Organization educational activities obtained from web-based surveys of World Stroke Organization Members, supplemented by interviews with international stroke support organizations. The workshop included over 50 international participants, selected to represent a balance of age, gender, geographical region, and different levels of health resources. Participants also included members of the World Stroke Organization Education Committee, the World Stroke Academy, stroke support organizations, and the International Journal of Stroke editorial board. The workshop focused on understanding more about educational needs (at all levels), with emphasis on resource-limited settings. Three broad questions were posed: (1) What are the key educational needs: (a) in your region, (b) from your perspective (e.g. stroke support organization)? (2) Do the current educational activities offered by World Stroke Organization and WSA meet your needs? (3) What could World Stroke Organization/World Stroke Academy offer in your region that would meet your needs? The facilitated discussions were recorded, and the results transcribed and summarized by members of the World Stroke Organization Education Committee. Five key needs were identified: 1. Collaborative interdisciplinary, training in both stroke care and how to advocate for stroke. 2. Educational materials provided in a wider range of formats that could be adapted to local circumstances and clinical practices. 3. Educational activities for healthcare providers and stroke support organizations organized regionally, with the World Stroke Organization providing organizational support, and a pool of experts, therapists, nurses, etc. to deliver locally relevant materials. 4. Clear and authoritative online resources, where it is easy to find key policy and protocol guidance. 5. A range of online interactive education and training resources to help build knowledge and competence in stroke care. The results of the workshop have been presented to the World Stroke Organization Board and will be used to help to guide the educational initiatives of the World Stroke Organization and World Stroke Academy going forward.

World Stroke Congress Abstracts, 2018 – Late breaking submissions

Free accessAbstractFirst published online October 20, 2018World Stroke Congress Abstracts, 2018 – Late breaking submissionsVolume 13, Issue 2_supplhttps://doi.org/10.1177/1747493018802481

World Stroke Congress Abstracts, 2018

World Stroke Congress Abstracts, 2018

World Stroke Congress Abstracts, 2018 – Late registration

World Stroke Congress Abstracts, 2018 – Late registration

Index for the 10th World Stroke Congress 2016 abstracts.

Index for the 10th World Stroke Congress 2016 abstracts.

Extra abstracts for the 10th World Stroke Congress, 2016

Free accessAbstractFirst published online October 26, 2016Extra abstracts for the 10th World Stroke Congress, 2016Volume 11, Issue 3_supplhttps://doi.org/10.1177/1747493016672394

Abstracts for the 10th World Stroke Congress, 2016

Free accessAbstractFirst published online October 26, 2016Abstracts for the 10th World Stroke Congress, 2016Volume 11, Issue 3_supplhttps://doi.org/10.1177/1747493016670567

Stroke Treatment: Current News and Developments

Several studies regarding the treatment of both acute ischemic and hemorrhagic stroke, and the secondary prevention have been completed and presented in the first few months of this year. The main results of these controversial studies are discussed in this article. Neurothrombectomy is the new standard in the treatment of acute ischemic stroke. During the 9th World Stroke Congress in Istanbul, the treatment of acute stroke entirely changed with presentation of the positive results of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MrClean) study on October 28th, 2014, regarding the effectiveness of thrombectomy. Following the announcement of these positive results, data collection in other thrombectomy studies with similar designs was aborted and the results were subjected to analysis; all neurologists became enthusiastic about the positive results for which they had been waiting for (1). However, this enthusiasm has waned after a more careful evaluation of the situation, because many countries, including Turkey, do not have the economic capacity to broadly and ethically implement this treatment. Therefore, it is believed that it is time to reorganize and implement the national acute stroke treatment system (2). The use of previous methods is no longer possible. The results were striking and they cannot be ignored. The highly effective reperfusion evaluated in Multiple Endovascular Stroke collaboration pooled data from five trials and found that the number needed to treat with endovascular thrombectomy to reduce disability by at least one level on the modified Rankin scale for one patient was 2.6 (3). Of course, this rate is a very rare; a fairly low rate in medicine. However, thrombectomy should be performed within 6-12 hours after stroke, so patients must be referred to eligible treatment centers within this short period of time known as the “therapeutic window.” In this case, regional regulations and national dissemination seems to be obligatory. Stroke can be observed everywhere, not only in metropoles, and every patient with severe stroke can only be treated in this way. Turkey was one of the last countries in Europe to initiate intravenous thrombolytic treatment. To avoid a similar situation in thrombectomy, and for the benefit of our patients and people, this scientific data must be implemented in Turkey with a collaborative and multidisciplinary approach. It is clear that Turkish Neurological Society should undertake the most critical role in this context. Low-dose intravenous thrombolytic treatment is not more effective in acute ischemic stroke. In the Enhanced Control of Hypertension and Thrombolysis Stroke Study, low-dose (0.6 mg/kg) and standard dose (0.9 mg/ kg) intravenous tissue plasminogen activator (tPA) were compared in 3.310 patients within 4.5 hours of the onset of stroke (4). The primary outcome was death or disability at 90 days, and was found similar in both groups (53.2% with low-dose tPA and 51.1% with standard dose). However, although mortality rates were less with low-dose, disability rates tended to be higher. This study suggests that 19 patients would not die if 1.000 patients were given low-dose tPA instead of a standard dose, but an extra 40 patients would be disabled. Also, major symptomatic intracerebral hemorrhage was less with low-dose tPA (1% vs. 2.1%). Although

ESUS and INTERACT.

In this edition of IJS new therapeutic opportunities are highlighted. First, a metanalysis of all the trials so far of tenectaplase versus alteplase for acute stroke thrombolysis using individual patient data, clearly tenectaplase has great promise as a more effective, and safer form of thrombolysis but phase III, level 1 evidence is required, such as may be generated from the ongoing TASTE trial. Second, interesting data from the embolic stroke of unknown embolic stroke of undetermined source (ESUS) global registry provides additional background for the opportunity for new interventions such as the novel oral anticoagulants (NOACS). They found about 1/6 of all ischemic strokes were in the ESUS category and that they generally were younger, had milder deficits, and were usually treated with antiplatelet agents. This should prime us for the results of such trials as RE-SPECT ESUS, and NAVIGATE ESUS. Those who have been following the INTERACT studies will be interested to see that a post hoc analysis of the entire data set for the use of heparin prophylactically for thromboembolic events within seven days of ICH had a poor outcome, a result which should influence clinical practice. Finally, our fascinating series profiling young stroke investigators from around the globe continues with the spotlight on Dar Dowlatshahi from Canada. We hope to see you at the coming World Stroke Congress!

9th world stroke congress, 22-25 october 2014, istanbul, Turkey.

9th world stroke congress, 22-25 october 2014, istanbul, Turkey.

Welcome letter.

Welcome letter.

7th world stroke congress.

The 7th World Stroke Congress was held in Coex Center, Seoul, Korea from Oct 13- 16, 2010. About 2800 people attended the meeting which was organized by Kenes International. 504 posters were presented comprising of 52 plenary sessions and 14 key note address. As the previous meetings had been held in Kyoto, Vancouver, Munich, and Vienna, Seoul was a welcome change as the new venue for deliberations on Stroke. This meeting was sponsored by Otsuka Pharmaceutical Co Ltd, Pfizer, Bayer Healthcare. Allergen, Boehringa Inghleim, Bristol-Myers and Sanofi-Aventis Korea etc. Various organizations focusing on Stroke awareness were formally recognized for their contributions. This included the Lalitha Hospital, Guntur, India and a Bronze medal was awarded to Brazilian Academy of Stroke. The Srilankan stroke group was recognized for media campaigns, web conferences, publishing booklets and evolving national strategy on Stroke. A competition was also launched for suggesting an attractive and International symbol for Stroke. doi : 10.5214/ans.0972.7531.1017411

Abstracts

This journal suppl. entitled: Special Issue: World Stroke Congress 2010, 13-16 October 2010, Seoul, Republic of Korea